Nanox (NASDAQ: NNOX) announced that its subsidiary, Nanox AI Ltd., has entered into a distribution agreement with Technologic s.r.l., an Italian company affiliated with Tecnologie Avanzate, to commercialize its AI-powered bone health solution, HealthOST, in Italy. The agreement is intended to expand Nanox AI's commercial presence in the Italian market, leveraging Technologic's experience and local market knowledge. HealthOST analyzes eligible routine CT scans to provide qualitative and quantitative assessments of the spine, helping clinicians identify patients who may benefit from further evaluation for musculoskeletal conditions such as osteoporosis.
This distribution agreement matters because it represents a tangible step in Nanox's strategy to drive the global transition to preventive health care. By partnering with an established Italian distributor, Nanox AI can accelerate the adoption of HealthOST in a key European market, potentially leading to earlier detection of osteoporosis and other bone health issues. Osteoporosis is a major public health concern, often undiagnosed until fractures occur. HealthOST's ability to extract actionable bone health information from routine CT scans—without additional imaging or radiation—could significantly improve patient outcomes while reducing costs. The move also signals growing acceptance of AI-based tools in clinical workflows, which may encourage broader adoption across Europe and beyond.
Nanox's broader ecosystem includes Nanox.ARC, a cost-effective 3D multi-source digital tomosynthesis imaging system; Nanox.AI, a suite of AI algorithms that augment routine CT interpretation; Nanox.CLOUD, a cloud platform for secure data management and advanced analytics; Nanox.MARKETPLACE and USARAD Holdings, which provide remote radiology and teleradiology services; and Nanox Health IT, which offers RIS, PACS, AI, and dictation solutions. By integrating imaging technology, AI, cloud infrastructure, clinical expertise, and health IT, Nanox seeks to lower barriers to adoption, improve utilization, and advance preventive care worldwide.
For investors, the Italian distribution deal could serve as a catalyst for revenue growth in Europe and validate Nanox's AI solutions in real-world clinical settings. The latest news and updates relating to NNOX are available in the company's newsroom at http://ibn.fm/NNOX. To view the full press release, visit https://ibn.fm/y9Zro.
About BioMedWire: BioMedWire ("BMW") is a specialized communications platform focused on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. For more information, visit https://www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website: https://www.BioMedWire.com/Disclaimer.
